Investors have circled back to healthcare stocks this year, and they’re likely to stick around. If they came for the ...

Cantor Fitzgerald initiated coverage of Amgen with an Overweight rating and $405 price target. The firm views Amgen’s obesity ...

Fintel reports that on September 27, 2024, Cantor Fitzgerald initiated coverage of Amgen (NasdaqGS:AMGN) with a Overweight ...

Cantor initiated Amgen (AMGN) coverage with an overweight rating, asserting it was a “big believer” in the biotech company’s ...

On 4, 2024, Amgen, Inc. filed a notice of data breach with the Attorney General of Massachusetts after discovering that ...

Led by strong returns for shares of Amgen and Chevron, the Dow Jones Industrial Average is climbing Friday afternoon.

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National Medical Products Administration in China has ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Rheumatologists and lab specialists generally support consumers' ability to access tests without a doctor's order, but they remain aware of the possible harms that can come with practice.

Amgen (AMGN) is up more than +1% after Cantor Fitzgerald initiated coverage on the stock with a recommendation of overweight with a price target of $405. HP Inc. (HPQ) is down more than -4% to lead ...

The US stock market opened higher on Friday, September 27, as soft inflation data fuels investors’ expectation of further ...